Cardiogeni PLC - Board Appointment of (Lord) James Nicholas Bethell

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

29 August 2025

Cardiogeni PLC

("Cardiogeni" or the "Company")

Cardiogeni Announces the Board Appointment of (Lord) James Nicholas Bethell

Cardiogeni (AQSE: CGNI), the UK clinical stage biotechnology company founded in 2007 by Nobel Laureate Professor Sir Martin Evans to develop innovative heart failure medicines, is pleased to announce that (Lord) James Nicholas Bethell will be appointed to the board as a non-executive director of the Company with immediate effect.

Lord Bethell is an entrepreneur, former health minister and champion for public health. He has a twenty-year track record working across government, media and industry, working at The Sunday Times, the US Senate, the EU Commission and the British government. He has built and sold communications companies and helped make the Ministry of Sound a global success story. As a minister at the Department for Health and Social Care, he helped lead the UK national response to the COVID-19 pandemic. He holds an MA (Hons) in History from the University of Edinburgh.

Lord Bethell is currently a member of the House of Lords, Trustee of the Royal Society of Public Health, chairman of Business for Health, a Fellow at King's College London and a senior counsel to several health companies.

As at the date of this announcement, Lord Bethell has no beneficial interest in the Company.

Save as set out in this announcement, there are no further details to be disclosed under Rule 4.9 of the Aquis Access Rules for Companies in respect of Lord Bethell.

END

About Cardiogeni

Founded by Nobel Laureate, Professor Sir Martin Evans, the Cardiogeni Group is developing a new class of life-saving cellular medicines. The Group's platform technology enables the creation of unique (living) cells that are engineered with a specific therapeutic function.

The Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel epigenetic cellular reprogramming technology was developed in-house by Professor Sir Martin Evans and the platform along with the pipeline of medicines in development are protected by a portfolio of ~100 international patents and trademarks.

CLXR-001 targets heart failure which will affect 1 in 4 people in their lifetime and is not reversible or curable. CLXR-001 consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration whose mechanism of action is to regenerate damaged heart tissue and restoration of improved heart function improving both the life expectancy and quality of life of patients.

CLXR-001 targets the cardiac market niche of CABG surgery with ~400,000 patients per year in the US alone. The Group's two follow-on products target larger cardiac market segments of stent treatment (over two million patients per year) and myocardial infarction (heart attack, over one million patients per year). Each of the products has the potential to become a first or best-in-class blockbuster ($1B in annual sales) medicine

CLXR-001 has successfully completed an EU Phase II investigator sponsored clinical trial in which patients showed a statistically significant (P<0.05) improvement in all end-point targets including heart function, reduction in heart scarring and an improvement in quality of life.

CLXR-001 has received regulatory approval to begin a randomized controlled trial from the national regulatory authority of a European Union member country and this trial has begun dosing patients with interim data expected to read-out within 18 months.

The Company's admission document is available to view on its website: www.cardiogeni.com

The Directors of Cardiogeni accept responsibility for this announcement.

For further information please contact: